
Education and Training
- Hematology/Oncology Fellowship, Medicine, Duke University School of Medicine, 2014 - 2017
- Internal Medicine Residency, Indiana University, School of Medicine, 2011 - 2014
- D.O., University of New England, 2011
Grants
- A Phase 2, Open-Label, Single-Arm Study of Single-Dose Lead-In and Neoadjuvant Trilaciclib and Chemotherapy in Patients with Early-Stage Triple Negative Breast Cancer (TNBC)
- A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
- A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer
- TBCRC 047
- GMI-1359-210
- Beyond PD1: An immunotherapeutic strategy to stimulate and enable both T-cell and B-cell responses in immunosuppressive and non-mutated metastatic breast cancer
- A Phase II randomized study to evaluate the immunologic and antitumor activity of concurrent VRP-HER2 vaccination and Pembrolizumab for patients with advanced HER2-overexpressing breast cancer
- Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
- A Randomized Phase II clinical trial assessing the Efficacy and Safety of MK-3475 (pembrolizumab) in combination with carboplatin and gemcitabine in patients with metastatic triple negative breast cancer
- A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINES AS ADJUVANT THERAPY IN PATIENTS
- Phase II Study of Combination Ruxolitinib (INCB018424) with Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer protocol # TBCRC 039
- Regional Oncolytic Poliovirus Immunotherapy for Breast Cancer